ARTICLE | Clinical News
Unituxin dinutuximab regulatory update
June 1, 2015 7:00 AM UTC
EMA’s CHMP recommended approval of Unituxin dinutuximab from United Therapeutics to treat high-risk neuroblastoma in patients aged 12 months to 17 years. Specifically, it is recommended in combination...